Literature DB >> 31130467

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Gianluca Civenni1, Roberto Bosotti1, Andrea Timpanaro1, Ramiro Vàzquez1, Jessica Merulla1, Shusil Pandit1, Simona Rossi1, Domenico Albino1, Sara Allegrini1, Abhishek Mitra1, Sarah N Mapelli2, Luca Vierling1, Martina Giurdanella1, Martina Marchetti1, Alyssa Paganoni1, Andrea Rinaldi1, Marco Losa1, Enrica Mira-Catò1, Rocco D'Antuono3, Diego Morone3, Keyvan Rezai4, Gioacchino D'Ambrosio5, L'Houcine Ouafik6, Sarah Mackenzie7, Maria E Riveiro7, Esteban Cvitkovic8, Giuseppina M Carbone1, Carlo V Catapano9.   

Abstract

Cancer stem cells (CSCs) contribute to disease progression and treatment failure in human cancers. The balance among self-renewal, differentiation, and senescence determines the expansion or progressive exhaustion of CSCs. Targeting these processes might lead to novel anticancer therapies. Here, we uncover a novel link between BRD4, mitochondrial dynamics, and self-renewal of prostate CSCs. Targeting BRD4 by genetic knockdown or chemical inhibitors blocked mitochondrial fission and caused CSC exhaustion and loss of tumorigenic capability. Depletion of CSCs occurred in multiple prostate cancer models, indicating a common vulnerability and dependency on mitochondrial dynamics. These effects depended on rewiring of the BRD4-driven transcription and repression of mitochondrial fission factor (Mff). Knockdown of Mff reproduced the effects of BRD4 inhibition, whereas ectopic Mff expression rescued prostate CSCs from exhaustion. This novel concept of targeting mitochondrial plasticity in CSCs through BRD4 inhibition provides a new paradigm for developing more effective treatment strategies for prostate cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BET inhibitors; BRD4; MFF; OTX015/MK-8628; bromodomain and extra-terminal domain proteins; cancer stem cells; mitochondrial dynamics; mitochondrial fission; mitochondrial fission factor; prostate cancer

Year:  2019        PMID: 31130467     DOI: 10.1016/j.cmet.2019.05.004

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  25 in total

1.  miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.

Authors:  Yuki Takagawa; Yasuyuki Gen; Tomoki Muramatsu; Kousuke Tanimoto; Jun Inoue; Hiroyuki Harada; Johji Inazawa
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 11.454

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes.

Authors:  Antonino Passaniti; Arif Hussain
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  Mitochondrial dynamics in cancer stem cells.

Authors:  Dane T Sessions; David F Kashatus
Journal:  Cell Mol Life Sci       Date:  2021-02-13       Impact factor: 9.261

5.  Lactate Rewires Lipid Metabolism and Sustains a Metabolic-Epigenetic Axis in Prostate Cancer.

Authors:  Luigi Ippolito; Giuseppina Comito; Elisa Giannoni; Paola Chiarugi; Matteo Parri; Marta Iozzo; Assia Duatti; Francesca Virgilio; Nicla Lorito; Marina Bacci; Elisa Pardella; Giada Sandrini; Francesca Bianchini; Roberta Damiano; Lavinia Ferrone; Giancarlo la Marca; Sergio Serni; Pietro Spatafora; Carlo V Catapano; Andrea Morandi
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 13.312

6.  MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer.

Authors:  Jae Ho Seo; Young Chan Chae; Andrew V Kossenkov; Yu Geon Lee; Hsin-Yao Tang; Ekta Agarwal; Dmitry I Gabrilovich; Lucia R Languino; David W Speicher; Prashanth K Shastrula; Alessandra Maria Storaci; Stefano Ferrero; Gabriella Gaudioso; Manuela Caroli; Davide Tosi; Massimo Giroda; Valentina Vaira; Vito W Rebecca; Meenhard Herlyn; Min Xiao; Dylan Fingerman; Alessandra Martorella; Emmanuel Skordalakes; Dario C Altieri
Journal:  Cancer Res       Date:  2019-10-03       Impact factor: 12.701

7.  Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.

Authors:  Michelle M Williams; Nicole S Spoelstra; Spencer Arnesen; Kathleen I O'Neill; Jessica L Christenson; Jordan Reese; Kathleen C Torkko; Andrew Goodspeed; Emmanuel Rosas; Toru Hanamura; Sharon B Sams; Zheqi Li; Steffi Oesterreich; Rebecca B Riggins; Britta M Jacobsen; Anthony Elias; Jason Gertz; Jennifer K Richer
Journal:  Cancer Res       Date:  2020-11-12       Impact factor: 13.312

8.  Gene Signature Associated With Bromodomain Genes Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma.

Authors:  Junwan Lu; Changrui Qian; Yongan Ji; Qiyu Bao; Bin Lu
Journal:  Front Genet       Date:  2021-06-02       Impact factor: 4.599

9.  Epigenetic Reader BRD4 (Bromodomain-Containing Protein 4) Governs Nucleus-Encoded Mitochondrial Transcriptome to Regulate Cardiac Function.

Authors:  Soo Young Kim; Xin Zhang; Gabriele G Schiattarella; Francisco Altamirano; Thais A R Ramos; Kristin M French; Nan Jiang; Pamela A Szweda; Bret M Evers; Herman I May; Xiang Luo; Hongliang Li; Luke I Szweda; Vinicius Maracaja-Coutinho; Sergio Lavandero; Thomas G Gillette; Joseph A Hill
Journal:  Circulation       Date:  2020-10-28       Impact factor: 39.918

Review 10.  Mitochondria in cancer.

Authors:  Debora Grasso; Luca X Zampieri; Tânia Capelôa; Justine A Van de Velde; Pierre Sonveaux
Journal:  Cell Stress       Date:  2020-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.